Inozyme Pharma
![Inozyme_Logo_RGB_600x171.png](https://www.boa.ac.uk/static/f6acf23a-0521-4e29-9ff6f65bcc83331f/500x142_highestperformance__4a7c7e45a350/InozymeLogoRGB600x171.png)
Congress Stand 61B
www.inozyme.com
+1(857)330-4340 (Boston) 07484 135577 (UK Consultant)
[email protected]
Inozyme Pharma is a clinical-stage biotech company committed to restoring health and hope to patients suffering the debilitating effects of rare diseases of abnormal mineralization.
We are initially focused on developing a novel ENPP1 enzyme replacement therapy INZ-701, targeting genetic and non-genetic diseases which involve low levels of PPi and adenosine – including ENPP1 Deficiency, ABCC6 Deficiency and Calciphylaxis.